MorphoSys AG to Present at Five Investor Conferences in June

MARTINSRIED, GERMANY and MUNCHEN, GERMANY--(Marketwired - June 03, 2013) -

MorphoSys AG / MorphoSys to Present at Five Investor Conferences in June . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement. The management of MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) will present at five upcoming international investor conferences: Jefferies 2013 Global Healthcare Conference Date: June 6, 2013, 10:30am EDT (04:30pm CEST, 03:30pm BST) Venue: New York, USA Participants: Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG, Dr. Claudia Gutjahr-Löser, Head of Corporate Communications & Investor Relations Commerzbank Corporate Day Date: June 6, 2013 Venue: London, UK Participant: Jens Holstein, Chief Financial Officer of MorphoSys AG 6th DVFA Life Science Conference Date: June 18, 2013 Venue: Frankfurt, Germany Participants: Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG, Dr. Claudia Gutjahr-Löser, Head of Corporate Communications & Investor Relations Citi’s European Healthcare Conference Date: June 18, 2013 Venue: London, UK Participant: Jens Holstein, Chief Financial Officer of MorphoSys AG J.P. Morgan Cazenove European Healthcare Conference Date: June 24, 2013, 04:00pm BST (05:00pm CEST, 11:00am EDT) Venue: London, UK Participants: Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG, Dr. Claudia Gutjahr-Löser, Head of Corporate Communications & Investor Relations 

The PDF version of the presentation will be provided at www.morphosys.com. The link to the webcast will be filed under www.morphosys.com/conference-calls.

About MorphoSys:

MorphoSys developed HuCAL, the most successful antibody library technology in the pharmaceutical industry. By successfully applying this and other patented technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human healthcare. Together with its pharmaceutical partners, MorphoSys has built a therapeutic pipeline of more than 70 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, and Alzheimer’s disease, to name just a few. With its ongoing commitment to new antibody technology and drug development, MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys is listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates about MorphoSys, visit http://www.morphosys.com.

HuCAL(®), HuCAL GOLD(®), HuCAL PLATINUM(®), CysDisplay(®), RapMAT(®), arYla(®), Ylanthia(®) and 100 billion high potentials(®) are registered trademarks of MorphoSys AG.

Slonomics(®) is a registered trademark of Sloning BioTechnology GmbH, a subsidiary of MorphoSys AG.

This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company’s assumptions, actual results and actions may differ from those anticipated. MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned.

Media Release (PDF): http://hugin.info/130295/R/1706630/564980.pdf

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: MorphoSys AG via Thomson Reuters ONE [HUG#1706630]